Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

PubWeight™: 6.17‹?› | Rank: Top 1%

🔗 View Article (PMID 9683204)

Published in Lancet on July 18, 1998

Authors

L Sjöström1, A Rissanen, T Andersen, M Boldrin, A Golay, H P Koppeschaar, M Krempf

Author Affiliations

1: Sahlgrenska University Hospital, Göteborg, Sweden.

Articles citing this

2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ (2007) 9.10

The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring) (2006) 8.25

One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring) (2009) 4.08

Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med (2010) 3.73

Long-term drug treatment for obesity: a systematic and clinical review. JAMA (2014) 3.69

Treatment of obesity in primary care practice in the United States: a systematic review. J Gen Intern Med (2009) 2.89

Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ (2001) 2.86

Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care (2010) 2.50

Randomized clinical trials of weight loss maintenance: a review. J Cardiovasc Nurs (2008) 2.43

Obesity: a time bomb to be defused. Lancet (1998) 1.90

The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev (2011) 1.89

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA (2016) 1.78

Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ (2014) 1.62

Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis. CMAJ Open (2014) 1.58

The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol (2007) 1.54

Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev (2009) 1.46

The prevention and treatment of obesity. Dtsch Arztebl Int (2014) 1.44

Call for action: preventing and managing the expansive and expensive obesity epidemic. CMAJ (1999) 1.39

IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety. Evid Based Complement Alternat Med (2015) 1.36

Industry funding and the reporting quality of large long-term weight loss trials. Int J Obes (Lond) (2008) 1.32

Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol (2010) 1.20

Obese African-American women's perspectives on weight loss and bariatric surgery. J Gen Intern Med (2007) 1.20

Effects of weight loss on serum vitamin D in postmenopausal women. Am J Clin Nutr (2011) 1.12

Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res (2011) 1.06

Weight gain, obesity, and psychotropic prescribing. J Obes (2011) 1.02

Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol. CMAJ (2001) 1.00

Obesity: an overview on its current perspectives and treatment options. Nutr J (2004) 0.99

Randomised controlled trial of novel, simple, and well supervised weight reducing diets in outpatients. BMJ (1998) 0.97

Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS One (2012) 0.96

Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab (2004) 0.96

Obesity management: update on orlistat. Vasc Health Risk Manag (2007) 0.94

Extracts from "Clinical Evidence". Obesity. BMJ (2001) 0.93

Maintenance of weight loss in adolescents: current status and future directions. J Obes (2011) 0.93

Predictors of weight loss and maintenance in patients treated with antiobesity drugs. Diabetes Metab Syndr Obes (2011) 0.92

Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract (2013) 0.92

The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents. Diabetes Metab Syndr Obes (2010) 0.89

Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. Br J Pharmacol (2013) 0.89

Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. Gut (2000) 0.88

A two-year clinical lifestyle intervention program for weight loss in obesity. Food Nutr Res (2008) 0.88

Effectiveness of weight loss interventions for obese older adults. Am J Health Promot (2013) 0.87

Effectiveness of a psychosocial weight management program for individuals with schizophrenia. J Behav Health Serv Res (2014) 0.87

A natural fiber complex reduces body weight in the overweight and obese: a double-blind, randomized, placebo-controlled study. Obesity (Silver Spring) (2013) 0.87

Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br J Clin Pharmacol (2008) 0.86

Orlistat. No hurry.... Can Fam Physician (1999) 0.86

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes (2014) 0.86

Pediatric obesity: parallels with addiction and treatment recommendations. Harv Rev Psychiatry (2008) 0.85

Remodeling natural products: chemistry and serine hydrolase activity of a rocaglate-derived β-lactone. J Am Chem Soc (2014) 0.85

acp Best Practice No 168. The investigation and management of obesity. J Clin Pathol (2003) 0.82

Managing obesity in primary care: do our patients deserve better? Br J Gen Pract (1999) 0.82

Effects of a stimulant-free dietary supplement on body weight and fat loss in obese adults: a six-week exploratory study. Curr Ther Res Clin Exp (2003) 0.82

Treating obesity. Lost cause or new opportunity? Can Fam Physician (2000) 0.82

Assessment and management of obesity in childhood and adolescence. Nat Rev Gastroenterol Hepatol (2011) 0.82

Frequent Self-Weighing and Visual Feedback for Weight Loss in Overweight Adults. J Obes (2015) 0.81

Strategies for weight maintenance in adult populations treated for overweight and obesity: a systematic review and meta-analysis. CMAJ Open (2015) 0.80

The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat. Dig Dis Sci (2005) 0.80

The appropriateness of routine medication treatment for schizophrenia. Schizophr Bull (2008) 0.80

Preventive pharmacotherapy in type 2 diabetes mellitus. Indian J Endocrinol Metab (2012) 0.79

Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies. Obesity (Silver Spring) (2015) 0.79

The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. Br J Clin Pharmacol (2015) 0.79

Impact of orlistat-induced weight loss on diastolic function and heart rate variability in severely obese subjects with diabetes. J Obes (2010) 0.78

Successful weight loss and maintenance in everyday clinical practice with an individually tailored change of eating habits on the basis of food energy density. Eur J Nutr (2010) 0.78

Orlistat in the prevention of diabetes in the obese patient. Vasc Health Risk Manag (2008) 0.78

Drug treatment of obesity: from past failures to future successes? Br J Clin Pharmacol (2001) 0.78

Regulation of appetite to treat obesity. Expert Rev Clin Pharmacol (2011) 0.77

Long-term effects of lipase inhibition by orlistat on gastric emptying and orocecal transit time of a solid meal. J Gastroenterol (2008) 0.77

Skeletal muscle structural lipids improve during weight-maintenance after a very low calorie dietary intervention. Lipids Health Dis (2009) 0.76

Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis. PLoS Med (2016) 0.76

Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity. Expert Rev Endocrinol Metab (2010) 0.76

Tackling obesity: new therapeutic agents for assisted weight loss. Diabetes Metab Syndr Obes (2010) 0.76

Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study. J Obes (2015) 0.75

Mitochondria as pharmacological targets: the discovery of novel anti-obesity mitochondrial uncouplers from Africa's medicinal plants. Afr J Tradit Complement Altern Med (2011) 0.75

Pharmacological Interventions against Obesity: Current Status and Future Directions. Visc Med (2016) 0.75

Flushing away the fat. Weight loss during trials of orlistat was significant, but over half was due to diet. BMJ (1998) 0.75

Obesity. West J Med (2002) 0.75

Orlistat and weight loss. Lancet (1998) 0.75

Influence of intense multidisciplinary follow-up and orlistat on weight reduction in a primary care setting. BMC Fam Pract (2005) 0.75

Orlistat and weight loss. Lancet (1998) 0.75

Supplementation with dairy calcium and/or flaxseed fibers in conjunction with orlistat augments fecal fat excretion without altering ratings of gastrointestinal comfort. Nutr Metab (Lond) (2017) 0.75

Thylakoids reduce body fat and fat cell size by binding to dietary fat making it less available for absorption in high-fat fed mice. Nutr Metab (Lond) (2017) 0.75

Changing times for disinfection and sterilization procedures in general practice. Br J Gen Pract (1999) 0.75

American College of Endocrinology Pre-Diabetes Consensus Conference: part two. Diabetes Care (2008) 0.75

Orlistat associated with hypertension. Digit preference lays conclusions about orlistat open to doubt. BMJ (2001) 0.75

Orlistat after initial dietary/behavioural treatment: changes in body weight and dietary maintenance in subjects with sleep related breathing disorders. Nutr J (2011) 0.75

Changes in Body Weight From Young Adulthood to Middle Age and Its Association With Blood Pressure and Hypertension: A Cross-Sectional Study in Hong Kong Chinese Women. J Am Heart Assoc (2016) 0.75

Does orlistat cause acute kidney injury? Ther Adv Drug Saf (2012) 0.75

Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther (2016) 0.75

Weight loss medications in Canada - a new frontier or a repeat of past mistakes? Diabetes Metab Syndr Obes (2017) 0.75

Articles by these authors

How much physical activity is enough to prevent unhealthy weight gain? Outcome of the IASO 1st Stock Conference and consensus statement. Obes Rev (2003) 4.03

A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15

Breakfast skipping and health-compromising behaviors in adolescents and adults. Eur J Clin Nutr (2003) 2.35

GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet (2000) 2.11

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) (2011) 2.08

The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol (1994) 2.04

Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res (2010) 1.99

Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1987) 1.96

Open questions about metabolically normal obesity. Int J Obes (Lond) (2010) 1.83

Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev (2000) 1.83

Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism (1982) 1.79

Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes (1987) 1.76

Role of viscous guar gums in lowering the glycemic response after a solid meal. Am J Clin Nutr (1994) 1.65

Synergistic effect of polymorphisms in uncoupling protein 1 and beta3-adrenergic receptor genes on basal metabolic rate in obese Finns. Diabetologia (1998) 1.63

Distribution and heritability of BMI in Finnish adolescents aged 16y and 17y: a study of 4884 twins and 2509 singletons. Int J Obes Relat Metab Disord (1999) 1.52

Physical activity reduces the influence of genetic effects on BMI and waist circumference: a study in young adult twins. Int J Obes (Lond) (2008) 1.51

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med (2000) 1.51

Growth hormone, insulin-like growth factor I and cognitive function in adults. Growth Horm IGF Res (2000) 1.44

Cimetidine suspension as adjuvant to energy restricted diet in treating obesity. BMJ (1993) 1.44

Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet (2000) 1.42

REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year. Arch Cardiovasc Dis (2008) 1.42

Relationship between peripheral vascular disease and high plantar pressures in diabetic neuro-ischaemic patients. Diabetes Metab (2003) 1.41

Adrenocortical function in patients with ruptured aneurysm of the abdominal aorta. Intensive Care Med (1998) 1.41

Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus. Atherosclerosis (2001) 1.39

Energy expenditure and substrates oxidative patterns, after glucose, fat or mixed load in normal weight subjects. Eur J Clin Nutr (1997) 1.39

Effects of gender and age on the heritability of body mass index. Int J Obes (1991) 1.38

Pathways from obesity to diabetes. Int J Obes Relat Metab Disord (2002) 1.36

A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet (1999) 1.34

Analysis of the p63 gene in classical EEC syndrome, related syndromes, and non-syndromic orofacial clefts. J Med Genet (2002) 1.33

Dietary antioxidants and the risk of lung cancer. Am J Epidemiol (1991) 1.32

Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry (2005) 1.30

The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. Arch Intern Med (1992) 1.29

Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab (2004) 1.29

Danish experience of statutory right of patients to access hospital records. Lancet (1988) 1.26

Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1987) 1.24

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J Obes (Lond) (2010) 1.23

A descriptive study of weight loss maintenance: 6 and 15 year follow-up of initially overweight adults. Int J Obes Relat Metab Disord (2000) 1.23

Glucose-induced thermogenesis in nondiabetic and diabetic obese subjects. Diabetes (1982) 1.23

Leanness and lung-cancer risk. Int J Cancer (1991) 1.21

A meta-analytic investigation of linkage and association of common leptin receptor (LEPR) polymorphisms with body mass index and waist circumference. Int J Obes Relat Metab Disord (2002) 1.21

Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med (1998) 1.20

Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab (1999) 1.19

Growth hormone (GH) treatment decreases postprandial remnant-like particle cholesterol concentration and improves endothelial function in adult-onset GH deficiency. J Clin Endocrinol Metab (2000) 1.19

Risk factors for subarachnoid hemorrhage in a longitudinal population study. J Clin Epidemiol (1991) 1.19

Serum antioxidant vitamins and risk of cataract. BMJ (1992) 1.17

Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab (1999) 1.15

Predictors of major weight gain in adult Finns: stress, life satisfaction and personality traits. Int J Obes Relat Metab Disord (1998) 1.15

Correlation of primate red nucleus discharge with muscle activity during free-form arm movements. J Physiol (1993) 1.15

Weight-loss attempts and risk of major weight gain: a prospective study in Finnish adults. Am J Clin Nutr (1999) 1.14

Gait characteristics of diabetic patients: a systematic review. Diabetes Metab Res Rev (2008) 1.13

Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord (2001) 1.13

Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia (2011) 1.13

The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone. Metabolism (1994) 1.12

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord (2004) 1.12

Weight gain during treatment with valproate. Acta Neurol Scand (1984) 1.12

Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction. Acta Endocrinol (Copenh) (1993) 1.12

Are genetic determinants of weight gain modified by leisure-time physical activity? A prospective study of Finnish twins. Am J Clin Nutr (1997) 1.11

Incidence and outcomes of bulimia nervosa: a nationwide population-based study. Psychol Med (2008) 1.11

Genome-wide scan of obesity in Finnish sibpairs reveals linkage to chromosome Xq24. J Clin Endocrinol Metab (2000) 1.11

Risk factors associated with contrast sensitivity loss in diabetic patients. Graefes Arch Clin Exp Ophthalmol (1996) 1.10

Randomised controlled trial of a guided self-help treatment on the Internet for binge eating disorder. Behav Res Ther (2011) 1.09

Post-influenzal encephalitis during the influenza A outbreak in 1979/1980. J Neurol Neurosurg Psychiatry (1981) 1.09

Tracking of body size from birth to late adolescence: contributions of birth length, birth weight, duration of gestation, parents' body size, and twinship. Am J Epidemiol (2001) 1.09

The gait and balance of patients with diabetes can be improved: a randomised controlled trial. Diabetologia (2009) 1.08

Increased parathyroid hormone as a consequence of changed complex binding of plasma calcium in morbid obesity. Metabolism (1986) 1.08

The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int J Obes (1984) 1.08

Glycemic control in patients with diabetes in Finland. Diabetes Care (1999) 1.08

Genetic and environmental effects on body mass index during adolescence: a prospective study among Finnish twins. Int J Obes (Lond) (2009) 1.07

Intensive physical and psychosocial training program for patients with chronic low back pain. A controlled clinical trial. Spine (Phila Pa 1976) (1994) 1.07

Family history as a risk factor of coronary heart disease in patients under 60 years of age. Eur Heart J (1998) 1.07

Liver morphology in morbid obesity: a literature study. Int J Obes (1984) 1.06

Expression of fatty-acid-handling proteins in human adipose tissue in relation to obesity and insulin resistance. Diabetologia (2004) 1.06

Characterising metabolically healthy obesity in weight-discordant monozygotic twins. Diabetologia (2013) 1.06

Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR). Eur J Clin Invest (2000) 1.05

Cardiac parasympathetic activity is increased by weight loss in healthy obese women. Obes Res (2001) 1.05

Admission blood glucose and short term survival in primary intracerebral haemorrhage: a population based study. J Neurol Neurosurg Psychiatry (2005) 1.05

Effect of obesity on ambient plasma glucose, free fatty acid, insulin, growth hormone, and glucagon concentrations. J Clin Endocrinol Metab (1986) 1.02

Weight loss by very-low-calorie diets: effects on substrate oxidation, energy expenditure, and insulin sensitivity in obese subjects. Am J Clin Nutr (1992) 1.02

Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. Metabolism (1990) 1.01

Energy economy hampers body weight loss after gastric bypass. J Clin Endocrinol Metab (2000) 1.01

Randomized trial of diet and gastroplasty compared with diet alone in morbid obesity. N Engl J Med (1984) 1.01

Causes and consequences of obesity: the contribution of recent twin studies. Int J Obes (Lond) (2011) 1.01

Estrogen treatment improves spatial learning in APP + PS1 mice but does not affect beta amyloid accumulation and plaque formation. Exp Neurol (2004) 1.00

Early puberty and early sexual activity are associated with bulimic-type eating pathology in middle adolescence. J Adolesc Health (2001) 1.00

Amino acid variants in the human leptin receptor: lack of association to juvenile onset obesity. Biochem Biophys Res Commun (1997) 0.99

Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism (1987) 0.99

Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia (1999) 0.99

Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis (2009) 0.99

The inheritance of height in a Finnish population. Ann Hum Biol (1983) 0.98

Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes. Diabetologia (1987) 0.98

Factors influencing energy intake and body weight loss after gastric bypass. Eur J Clin Nutr (2002) 0.98

Metabolic normality in overweight and obese subjects. Which parameters? Which risks? Int J Obes (Lond) (2011) 0.98

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Diabet Med (2010) 0.98

Quality indicators for the prevention of type 2 diabetes in Europe--IMAGE. Horm Metab Res (2010) 0.97

Surveillance of noise exposure in the Danish workplace: a baseline survey. Occup Environ Med (2004) 0.97

Lumbar muscle fiber size and type distribution in normal subjects. Eur Spine J (1994) 0.96

Congruence on medication between patients and physicians involved in patient course. Eur J Clin Pharmacol (2003) 0.96

Identification of new sequence variants in the leptin gene. J Clin Endocrinol Metab (1998) 0.96